알레르기 및 자가면역질환 진단 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 검사 유형별, 진단 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Allergy And Autoimmune Disease Diagnostics Market Summary

The global allergy and autoimmune disease diagnostics market size was estimated at USD 11.38 billion in 2024 and is projected to reach USD 25.02 billion by 2033, growing at a CAGR of 5.41% from 2025 to 2033. This market addresses the detection and monitoring of immune-related conditions, spanning a wide range of allergic reactions and autoimmune disorders.

Growth is being supported by the rising incidence of chronic immune conditions, greater public and clinical awareness, and technological improvements in diagnostic modalities such as immunoassays and molecular platforms. Ongoing efforts to improve diagnostic accuracy, speed, and accessibility, especially through point-of-care formats and multiplex testing, are reshaping the landscape. Expanding laboratory infrastructure, integration of digital tools, and interest in personalized immunodiagnostics are contributing to early disease detection and long-term management strategies. Innovations in biomarker research and AI-driven analysis are expected to further support diagnostic precision in complex autoimmune profiles.

According to the National Health Interview Survey (NHIS), 2021, published by the U.S. Centers for Disease Control and Prevention (CDC) in a press release dated January 2023, nearly 1 in 3 adults and more than 1 in 4 children in the U.S. reported having a seasonal allergy, eczema, or food allergy. Around 6% of both adults and children suffer from a food allergy, with the rate being notably higher among Black, non-Hispanic individuals compared to other racial and ethnic groups. These figures reflect the growing diagnostic demand for allergy-related conditions across diverse populations, emphasizing the need for more accurate and inclusive testing approaches in the allergy and autoimmune disease diagnostics industry.

In addition, the market is witnessing greater integration of home-based and decentralized testing solutions, enabling broader access to diagnostics beyond traditional clinical settings. Collaborations between diagnostic developers, public health agencies, and private providers are enhancing the availability of tests in community health centers and pharmacies. These developments, combined with rising investments in immunology research and the expansion of diagnostic coverage under national health programs, are expected to strengthen the position of the allergy and autoimmune disease diagnostics market over the coming years.

Global Allergy And Autoimmune Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global allergy and autoimmune disease diagnostics market report based on product and service, diagnostics type, test type, end use, and region:

• Product and Service Outlook (Revenue, USD Million, 2021 - 2033)
• Allergy Diagnostics
  • Instruments
  • Consumables
  • Services
• Autoimmune Disease Diagnostics
  • Instruments
  • Consumables
  • Services
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Allergy Diagnostics
  • In vivo Test
  • Skin Prick Test
  • Intradermal Test
  • Patch Test
  • In vitro Test
  • Autoimmune Disease Diagnostics
  • Antinuclear Antibody Tests
  • Autoantibody Tests
  • C-reactive Protein (CRP)
  • Complete Blood Count (CBC)
  • Urinalysis
  • Others
• Diagnostics Type Outlook (Revenue, USD Million, 2021 - 2033)
• Allergy Diagnostics
  • Food
  • Dairy Products
  • Poultry Products
  • Tree Nuts
  • Peanuts
  • Shellfish
  • Wheat
  • Soys
  • Other Food Allergens
  • Inhaled
  • Drug
  • Other Allergens
• Autoimmune Disease Diagnostics
  • Systemic Autoimmune Disease Diagnostics
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Systemic Lupus Erythematosus (SLE)
  • Others
  • Localized Autoimmune Disease Diagnostics
  • Multiple Sclerosis
  • Type 1 Diabetes
  • Hashimoto's Thyroiditis
  • Idiopathic Thrombocytopenic Purpura
  • Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Allergy Diagnostics
  • Hospitals & Clinics
  • Diagnostics Laboratories
  • Research Institutions
  • Others
• Autoimmune Diagnostics
  • Hospitals & Clinics
  • Diagnostics Laboratories
  • Research Institutions
  • Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Allergy and Autoimmune Disease Diagnostics Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product and Service Segment
    • 1.1.1.2. Test Type Segment
    • 1.1.1.3. Diagnostics Type Segment
    • 1.1.1.4. End Use segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Allergy and Autoimmune Disease Diagnostics Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Product and Service and Test type Snapshot
• 2.3. Diagnostics Type Snapshot
• 2.4. End Use Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Allergy and Autoimmune Disease Diagnostics Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising Prevalence of Immune-Related Disorders
  • 3.4.2. Shift Toward Early and Personalized Diagnosis
  • 3.4.3. Expansion of Decentralized and Home-Based Testing
• 3.5. Market Restraint Analysis
  • 3.5.1. High Cost of Advanced Diagnostic Technologies
  • 3.5.2. Underdiagnosis and Limited Awareness in Emerging Markets:
  • 3.5.3. Regulatory and Reimbursement Barriers
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Allergy and Autoimmune Disease Diagnostics Market: Product and Service Estimates & Trend Analysis

• 4.1. Allergy and Autoimmune Disease Diagnostics Market: Product and Service Movement Analysis
• 4.2. Allergy Diagnostics
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.2. Instruments
    • 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.3. Consumables
    • 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.4. Services
    • 4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Autoimmune Disease Diagnostics
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.2. Instruments
    • 4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.3. Consumables
    • 4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.4. Services
    • 4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Allergy and Autoimmune Disease Diagnostics Market: Test Type Estimates & Trend Analysis

• 5.1. Allergy and Autoimmune Disease Diagnostics Market: Test Type Movement Analysis
• 5.2. Allergy Diagnostics
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.2. In vivo Test
    • 5.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.2.2. Skin Prick Test
      • 5.2.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.2.3. Intradermal Test
      • 5.2.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.2.4. Patch Test
      • 5.2.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.3. In vitro Test
    • 5.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.4. Autoimmune Disease Diagnostics
    • 5.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.4.2. 'Antinuclear Antibody Tests
      • 5.2.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.4.3. Autoantibody Tests
      • 5.2.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.4.4. C-reactive Protein (CRP)
      • 5.2.4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.4.5. Complete Blood Count (CBC)
      • 5.2.4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.4.6. Urinalysis
      • 5.2.4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.4.7. Others
      • 5.2.4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Allergy and Autoimmune Disease Diagnostics Market: Diagnostics Type Estimates & Trend Analysis

• 6.1. Allergy and Autoimmune Disease Diagnostics Market: Technology Movement Analysis
• 6.2. Allergy Diagnostics
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.2. Food
    • 6.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.2.2.2. Dairy Products
      • 6.2.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.2.2.3. Poultry Products
      • 6.2.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.2.2.4. Tree Nuts
      • 6.2.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.2.2.5. Peanuts
      • 6.2.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.2.2.6. Shellfish
      • 6.2.2.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.2.2.7. Wheat
      • 6.2.2.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.2.2.8. Soys
      • 6.2.2.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.2.2.9. Other Food Allergens
      • 6.2.2.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.3. Inhaled
    • 6.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.4. Drug
    • 6.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.5. Other Allergens
    • 6.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Autoimmune Disease Diagnostics
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. Systemic Autoimmune Disease Diagnostics
    • 6.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2.2. Rheumatoid Arthritis
      • 6.3.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2.3. Ankylosing Spondylitis
      • 6.3.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2.4. Systemic Lupus Erythematosus (SLE)
      • 6.3.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2.5. Others
      • 6.3.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Localized Autoimmune Disease Diagnostics
    • 6.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3.2. Multiple Sclerosis
      • 6.3.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3.3. Type 1 Diabetes
      • 6.3.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3.4. Hashimoto's Thyroiditis
      • 6.3.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3.5. Idiopathic Thrombocytopenic Purpura
      • 6.3.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3.6. Others
      • 6.3.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Allergy and Autoimmune Disease Diagnostics Market: End Use Estimates & Trend Analysis

• 7.1. Allergy and Autoimmune Disease Diagnostics Market: End Use Movement Analysis
• 7.2. Allergy Diagnostics
  • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.2. Hospitals & Clinics
    • 7.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.3. Diagnostics Laboratories
    • 7.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.4. Research Institutions
    • 7.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.5. Others
    • 7.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.3. Autoimmune Diagnostics
  • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. Hospitals & Clinics
    • 7.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Diagnostics Laboratories
    • 7.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Research Institutions
    • 7.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.5. Others
    • 7.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Allergy and Autoimmune Disease Diagnostics Market: Regional Business Analysis

• 8.1. Regional Market Snapshot
• 8.2. North America
  • 8.2.1. North America Allergy and Autoimmune Disease Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.2.2. Key Country Dynamics
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Reimbursement Scenario
    • 8.2.2.5. Competitive Scenario
  • 8.2.3. Canada
    • 8.2.3.1. Canada Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.3.2. Key Country Dynamics
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Reimbursement Scenario
    • 8.2.3.5. Competitive Scenario
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.4.2. Key Country Dynamics
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Reimbursement Scenario
    • 8.2.4.5. Competitive Scenario
• 8.3. Europe
  • 8.3.1. Europe Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.2.2. Key Country Dynamics
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Reimbursement Scenario
    • 8.3.2.5. Competitive Scenario
  • 8.3.3. Germany
    • 8.3.3.1. Germany Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.3.2. Key Country Dynamics
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Reimbursement Scenario
    • 8.3.3.5. Competitive Scenario
  • 8.3.4. Spain
    • 8.3.4.1. Spain Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.4.2. Key Country Dynamics
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Reimbursement Scenario
    • 8.3.4.5. Competitive Scenario
  • 8.3.5. France
    • 8.3.5.1. France Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.5.2. Key Country Dynamics
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Reimbursement Scenario
    • 8.3.5.5. Competitive Scenario
  • 8.3.6. Italy
    • 8.3.6.1. Italy Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.6.2. Key Country Dynamics
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Reimbursement Scenario
    • 8.3.6.5. Competitive Scenario
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.7.2. Key Country Dynamics
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Reimbursement Scenario
    • 8.3.7.5. Competitive Scenario
  • 8.3.8. Sweden
    • 8.3.8.1. Sweden Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.8.2. Key Country Dynamics
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Reimbursement Scenario
    • 8.3.8.5. Competitive Scenario
  • 8.3.9. Norway
    • 8.3.9.1. Norway Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.9.2. Key Country Dynamics
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Reimbursement Scenario
    • 8.3.9.5. Competitive Scenario
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Japan Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.2.2. Key Country Dynamics
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. Competitive Scenario
  • 8.4.3. China
    • 8.4.3.1. China Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.3.2. Key Country Dynamics
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. Competitive Scenario
  • 8.4.4. India
    • 8.4.4.1. India Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.4.2. Key Country Dynamics
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. Competitive Scenario
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.5.2. Key Country Dynamics
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Reimbursement Scenario
    • 8.4.5.5. Competitive Scenario
  • 8.4.6. Thailand
    • 8.4.6.1. Thailand Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.6.2. Key Country Dynamics
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Reimbursement Scenario
    • 8.4.6.5. Competitive Scenario
  • 8.4.7. Australia
    • 8.4.7.1. Australia Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.7.2. Key Country Dynamics
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Reimbursement Scenario
    • 8.4.7.5. Competitive Scenario
• 8.5. Latin America
  • 8.5.1. Latin America Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.2.2. Key Country Dynamics
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. Competitive Scenario
  • 8.5.3. Argentina
    • 8.5.3.1. Argentina Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.3.2. Key Country Dynamics
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Competitive Scenario
• 8.6. MEA
  • 8.6.1. MEA Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. South Africa Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.2.2. Key Country Dynamics
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. Competitive Scenario
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Saudi Arabia Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.3.2. Key Country Dynamics
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Scenario
    • 8.6.3.5. Competitive Scenario
  • 8.6.4. UAE
    • 8.6.4.1. UAE Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.4.2. Key Country Dynamics
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Scenario
    • 8.6.4.5. Competitive Scenario
  • 8.6.5. Kuwait
    • 8.6.5.1. Kuwait Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.5.2. Key Country Dynamics
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Scenario
    • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1. New Product and Service Launch
  • 9.2.2. Partnerships
  • 9.2.3. Acquisition
  • 9.2.4. Collaboration
  • 9.2.5. Funding
• 9.3. Key Company Market Share Analysis, 2024
• 9.4. Company Heat Map Analysis
• 9.5. Company Profiles
  • 9.5.1. THERMO FISHER SCIENTIFIC, INC.
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product and Service Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. HYCOR BIOMEDICAL
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product and Service Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (PERKINELMER, INC.)
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product and Service Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. OMEGA DIAGNOSTICS GROUP PLC
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product and Service Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. LINCOLN DIAGNOSTICS, INC.
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product and Service Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. AESKU.GROUP GMBH
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product and Service Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. MINARIS MEDICAL AMERICA, INC.
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product and Service Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. HOB BIOTECH GROUP CORP., LTD.
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product and Service Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. DASIT GROUP SPA
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product and Service Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. R-BIOPHARM AG
    • 9.5.10.1. Company Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product and Service Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. BIOMERIEUX
    • 9.5.11.1. Company Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Product and Service Benchmarking
    • 9.5.11.4. Strategic Initiatives
  • 9.5.12. SIEMENS HEALTHCARE GMBH
    • 9.5.12.1. Company Overview
    • 9.5.12.2. Financial Performance
    • 9.5.12.3. Product and Service Benchmarking
    • 9.5.12.4. Strategic Initiatives
  • 9.5.13. HOFFMANN-LA ROCHE LTD
    • 9.5.13.1. Company Overview
    • 9.5.13.2. Financial Performance
    • 9.5.13.3. Product and Service Benchmarking
    • 9.5.13.4. Strategic Initiatives
  • 9.5.14. ABBOTT
    • 9.5.14.1. Company Overview
    • 9.5.14.2. Financial Performance
    • 9.5.14.3. Product and Service Benchmarking
    • 9.5.14.4. Strategic Initiatives
  • 9.5.15. BECKMAN COULTER, INC.
    • 9.5.15.1. Company Overview
    • 9.5.15.2. Financial Performance
    • 9.5.15.3. Product and Service Benchmarking
    • 9.5.15.4. Strategic Initiatives
  • 9.5.16. DANAHER CORPORATION
    • 9.5.16.1. Company Overview
    • 9.5.16.2. Financial Performance
    • 9.5.16.3. Product and Service Benchmarking
    • 9.5.16.4. Strategic Initiatives
  • 9.5.17. QUEST DIAGNOSTICS
    • 9.5.17.1. Company Overview
    • 9.5.17.2. Financial Performance
    • 9.5.17.3. Product and Service Benchmarking
    • 9.5.17.4. Strategic Initiatives
  • 9.5.18. NOVA DIAGNOSTICS PTE LTD.
    • 9.5.18.1. Company Overview
    • 9.5.18.2. Financial Performance
    • 9.5.18.3. Product and Service Benchmarking
    • 9.5.18.4. Strategic Initiatives